YK 11

YK-11 Dragon Pharma — Overview

YK-11 Dragon Pharma is a steroidal selective androgen receptor modulator (SARM) at 10 mg per tablet — structurally DHT-derived but pharmacologically distinct from both conventional AAS and non-steroidal SARMs. Its defining property is dual-pathway activity: partial agonism at the androgen receptor combined with upregulation of follistatin, which suppresses myostatin — the protein that acts as the body's genetic ceiling on muscle mass. No other SARM in Dragon Pharma's lineup targets myostatin. The result is lean, dry muscle accumulation without estrogen-related water retention, at a potency level that places YK-11 closer to a mild AAS than to a typical research SARM. Available at Steroid Warehouse, YK-11 is formulated for intermediate to advanced users looking for a recomp or lean gaining cycle that goes beyond what conventional non-steroidal SARMs can deliver.

About the Compound: YK-11

YK-11 (systematic name: (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester) is a synthetic steroidal compound with a 4-ene-3-one core shared with classical androgens, making it structurally closer to DHT than to non-steroidal SARMs such as ostarine or LGD-4033. This structural similarity is what gives YK-11 its steroidal SARM classification and distinguishes its pharmacological footprint from the rest of the SARM class.

• Partial androgen receptor agonism: YK-11 binds the androgen receptor but induces a different receptor conformation than full AR agonists like testosterone or DHT. It activates a selected subset of androgen-responsive genes — specifically those associated with anabolic processes — while producing a weaker androgenic signal than a full agonist at equivalent doses. This partial agonism profile is the basis for its SARM classification despite its steroidal structure.
• Myostatin inhibition via follistatin upregulation: YK-11's most studied and clinically significant secondary mechanism is its ability to induce follistatin expression in muscle cells. Follistatin is an endogenous antagonist of myostatin — the TGF-β family protein that limits skeletal muscle hypertrophy. By upregulating follistatin, YK-11 reduces the myostatin-mediated ceiling on muscle mass. This mechanism is independent of androgen receptor signaling and is not shared by any other SARM in the catalog. The practical implication is lean mass accumulation that may exceed what androgen receptor stimulation alone could produce.
• Steroidal structure and hepatotoxicity: Unlike non-steroidal SARMs (ostarine, LGD-4033), YK-11's steroidal core places it in a different hepatic risk category. Oral steroidal compounds with structural similarity to 17α-alkylated androgens carry measurable hepatotoxic potential. YK-11 is not confirmed 17α-alkylated in the classical sense, but liver enzyme monitoring is warranted — clinical and field data suggest ALT/AST elevation at moderate to high doses.
• HPG suppression: YK-11 suppresses LH and FSH more significantly than non-steroidal SARMs at typical doses. Users who report no suppression at 5 mg/day are outliers — at 10–15 mg/day, HPG suppression sufficient to require PCT is the expected outcome.

What YK-11 Does

• Lean, dry muscle accumulation: YK-11 produces lean mass gains without estrogen-related water retention — a consistently reported characteristic across user data and the limited in-vitro literature. The gains are not as rapid as those from full AR agonists but they are cleaner. Over a 6–8 week cycle most users report 4–8 lb of lean tissue retention that holds after cycle, not the inflated wet-weight numbers seen with aromatizing compounds.
• Myostatin inhibition — the genetic ceiling effect: The follistatin-mediated suppression of myostatin represents a mechanistic advantage that standard AAS and other SARMs do not have. Myostatin sets an individual ceiling on muscle cross-sectional area. Reducing myostatin activity — even transiently during a cycle — allows muscle fibers to hypertrophy beyond the point that androgen receptor stimulation alone would support. This is the core argument for YK-11 over LGD-4033 or RAD-140 for users who have already maximized response to conventional anabolic compounds.
• Strength increase: Strength gains accompany the lean mass accumulation. Users report increases in working weights across compound movements within the first 2–3 weeks — earlier than the lean mass becomes visually apparent. The mechanism is both direct AR-mediated neuromuscular activation and the anabolic support to connective tissue and muscle fiber remodeling.
• Recomposition effect: At maintenance or mild caloric deficit, YK-11 supports simultaneous fat loss and lean mass gain — the recomp outcome that most anabolic protocols produce poorly. The combination of lean anabolic activity without water retention makes it particularly useful for athletes who need to improve body composition without bulk-phase mass accumulation.
• No estrogenic activity: No aromatization, no water retention, no estrogen-mediated side effects. No aromatase inhibitor is required during a YK-11 solo cycle.

Who It's For

YK-11 occupies a specific position in the SARM hierarchy — not a beginner compound, not an AAS replacement, but a targeted tool for users who have exhausted what non-steroidal SARMs offer.

• What differentiates YK-11 from similar options: YK-11 is the only compound in the Dragon Pharma SARM lineup that targets myostatin via follistatin upregulation. LGD-4033 and MK-2866 are pure AR agonists with no myostatin mechanism. S-23 is a more potent AR agonist but also lacks myostatin activity. MK-677 raises GH/IGF-1 but does not affect AR or myostatin directly. YK-11 is therefore the only option when the goal is to push beyond the AR-stimulation ceiling into myostatin-pathway territory.
• The specific scenario where it's the better choice: Intermediate to advanced users who have run multiple SARM or mild AAS cycles and are finding lean mass response diminishing. Athletes in physique sports running lean recomp cycles where adding wet mass from aromatizing compounds is counterproductive. Users who want a steroidal-level anabolic stimulus without full AAS commitment. Anyone specifically targeting the follistatin-myostatin pathway for a cycle.
• Who should choose something else: First-time SARM users — start with MK-2866 (Ostarine) to establish baseline SARM response before escalating to a compound with this suppression and hepatic profile. Anyone unwilling or unable to run post-cycle therapy — YK-11's HPG suppression makes PCT non-optional at typical doses. Women: YK-11's androgenic and myostatin-modulating activity in females is insufficiently characterized; the risk-benefit profile does not support use.

YK-11 vs Alternatives

Combinations

Side Effects and How to Manage Them

YK-11's side effect profile reflects its position between non-steroidal SARMs and mild AAS. The steroidal structure introduces hepatic risk absent from compounds like ostarine, and the suppression profile is more aggressive than most SARMs. Proactive monitoring is more important here than with beginner SARM compounds.

Bloodwork Monitoring

Post-Cycle Recovery

PCT after YK-11 is more similar to mild AAS recovery than to the light SARMs protocols adequate for Ostarine at 20 mg/day. Expect 4 weeks of SERM-based PCT minimum; confirm LH/FSH recovery via bloodwork before ending the protocol.

For full PCT timing and dosing protocols see the PCT guide.

References